Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324912 | 0.88 | USP2 (0.40) | USP2SMN1; SMN2GRIN2BGRIN2CGPR119 | |
| SCHEMBL17324919 | 0.81 | USP2 (0.40) | USP2SMN1; SMN2GPR119USP30DDB1 | |
| SCHEMBL19518166 | 0.80 | USP2 (0.39) | USP2SMN1; SMN2GPR119MAPTRECQL | |
| SCHEMBL23015953 | 0.80 | USP2 (0.45) | USP2SMN1; SMN2GPR119TSHRALOX15 | |
| SCHEMBL15544785 | 0.80 | USP2 (0.40) | USP2SMN1; SMN2GRIN2BGRIN2CGPR119 | |
| SCHEMBL20555671 | 0.79 | USP2 (0.38) | USP2SMN1; SMN2GPR119USP30DDB1 | |
| SCHEMBL20555714 | 0.78 | OPRM1 (0.49) | USP2SMN1; SMN2GRIN2BGRIN2CGPR119 | |
| SCHEMBL17324924 | 0.78 | OPRM1 (0.49) | USP2SMN1; SMN2GRIN2BGRIN2CGPR119 | |
| SCHEMBL19518143 | 0.78 | OPRM1 (0.49) | USP2SMN1; SMN2GRIN2BGRIN2CGPR119 | |
| SCHEMBL20621868 | 0.77 | USP2 (0.36) | USP2SMN1; SMN2GRIN2BGRIN2CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| EP-3377500-B1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2022-10-19 | — | — | EP | disclosed |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2021-04-22 | — | — | US | disclosed |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2021-04-22 | — | — | US | disclosed |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | disclosed |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | disclosed |
| EP-3149006-B1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| EP-3149006-B1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-20190177337-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-06-13 | — | — | US | disclosed |
| US-20190177337-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-06-13 | — | — | US | disclosed |
| US-10246465-B2 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-04-02 | — | — | US | disclosed |
| US-10246465-B2 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-04-02 | — | — | US | disclosed |
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-11-15 | — | — | US | disclosed |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-02 | — | — | US | disclosed |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-02 | — | — | US | disclosed |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-02 | — | — | US | disclosed |
| WO-2015185209-A1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | USP2 2713/4885SMN1; SMN2 3963/4885GRIN2B 83/4885 |
| US-10246465-B2 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | USP2 2147/4885SMN1; SMN2 708/4885GRIN2B 133/4885 |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | USP2 2713/4885SMN1; SMN2 3963/4885GRIN2B 83/4885 |
| US-20190177337-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | USP2 2147/4885SMN1; SMN2 708/4885GRIN2B 133/4885 |
| US-20170313723-A1 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, SIGMAR1, OPRM1 | USP2 1847/4885SMN1; SMN2 775/4885GRIN2B 128/4885 |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | USP2 2713/4885SMN1; SMN2 3963/4885GRIN2B 83/4885 |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | USP2 2725/4885SMN1; SMN2 4000/4885GRIN2B 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.